



EUROPEAN
COMMISSION

Community Research

Strengthening EU-China S&T Partnership in Health Research




Octavi Quintana Trias
Director of Health Research
European Commission
DG Research



3rd Country Participation in FP6 Health Research

*Number of 3rd country participants in Health projects
(including SARS call)*



**In total: 230 participants from
42 third countries in 548 projects**





EUROPEAN
COMMISSION

Community Research

Chinese Participation in FP6 Health Research

- **Altogether 28 Chinese participants in 16 projects**
 - includes SARS projects
- **total EC contribution to Chinese participants in excess of 3 million EURO**





EUROPEAN
COMMISSION

Community Research

SSA PROJECT EXAMPLE :

EFBIC Yellow

European Focus on Biotechnology in China

- a collaborative project between BioMedicoForum, Europe Unlimited and China National Center for Biotechnology Development
- EFBIC aims at encouraging and facilitating cooperative research in life sciences between the China and Europe
- EFBIC Yellow aims at promoting partnership, joint ventures and collaboration between European Biotech SMEs, European regional agencies and the Chinese Biotech community
- Supported through a € 500.000 grant from directorate Health





EUROPEAN
COMMISSION

Community Research

The Seventh Framework Programme 2007-2013





1. Health

Biotechnology, generic tools and technologies for human health

Translating research for human health

Optimising the delivery of healthcare to European citizens



Collaborative research in Health

1: Biotechnology, generic tools and technologies

- **High-throughput research**
(enhancing data generation, standardisation, acquisition & analysis).
- **Detection, diagnosis and monitoring**
(with emphasis on non-invasive or minimally invasive approaches).
- **Innovative therapeutic approaches and interventions**
(with potential application in many diseases and disorders).
- **Predicting suitability, safety and efficacy of therapies**
(biological markers, in vivo and in vitro methods and models, including simulation, pharmacogenomics, targeting approaches and alternatives to animal testing)



Collaborative research in Health

2: Translating research for human health

- Integrating biological data and processes:
(large-scale data gathering, systems biology)
- Research on the brain and related diseases, human development and ageing
- Translational research in infectious diseases: to confront major threats to public health (antimicrobial drug resistance, HIV/AIDS, malaria, TB, emerging epidemics)
- Translational research in other major diseases:
(cancer, cardiovascular disease, diabetes/obesity; rare diseases; and other chronic diseases)



Collaborative research in Health

- ### 3: Optimising the delivery of health care to European citizens
- Enhanced health promotion and disease prevention (providing evidence of best public health measures – life styles, interventions, special focus on mental health, etc.)
 - Translating clinical research into clinical practice (patient safety, better use of medicines, benchmarking, pharmacovigilance, etc.)
 - Quality, solidarity and sustainability of health systems (organisational and financial aspects, health systems, etc.)



International Cooperation in FP7

Strategic objectives:

- Support partnerships with 3rd countries in selected fields
- Address specific problems that third countries face or that have a global character, on the basis of mutual interest and mutual benefit
- S&T cooperations to reinforce the Community's external relations and other relevant policies



International Cooperation in FP7

2 different avenues:

1. All activities open for International Cooperation

- International Cooperation Partner Countries (ICPCs) can participate in projects and receive EC funding as in FP6
- Industrialised countries may be funded if their participation is seen as essential for the project
- Minimum number of participants: 3 from MS/AS

2. Specific International Cooperation Actions

- Address specific issues that partner countries face or have a global character, on the basis of mutual interest and benefit
- Minimum number of participants: 2+2 (2 from MS/AS + 2 from ICPCs)



International Cooperation in FP7

Topics examples from the first SICA* call with special Chinese interest:

Collaborative projects:

Influenza research in collaboration with Asian partners.

To support influenza research. Including: identification or verification of new targets or drug candidates; prophylactic (containment and mitigation) and therapeutic approaches or surveillance research.

Coordination and Support Actions:

International cooperation in Traditional Chinese Medicine.

To promote and support networking of research activities in Traditional Chinese Medicine in Europe and China paving the way for further research collaboration

Promotion and facilitation of international cooperation in relevant areas.

For stimulating the creation of research consortia and the identification of priorities of common interest in health research.

*Specific International Cooperation Actions



Coordination and Support Actions

Possible activities:

- **Scientific workshops/seminars**
 - travel costs of invited speakers
 - other organisation costs
- **Training courses**
 - salaries of teachers
 - organisational costs, incl. premises, travel etc.
- **Salary of a project manager**
 - small scale studies, analysis etc.
- **Dissemination activities**
 - website, publications



Deeper collaboration through joint calls

Approach:

- **Identification of priority collaboration areas in Health**
 - high-throughput research
 - infectious (or other) diseases
- **Each side provides its share of funds**
 - FP7 collaborative programme
 - Chinese funds
- **Coordinated issuing of calls and evaluation**
 - precondition: collaboration between EU and CN groups
 - other applicable rules apply (e.g. FP7 rules for EU side)
- **Jointly organised dissemination activities**
 - highlighting achievements on either side



EU-China Cooperation in FP7

Issues at stake:

Great willingness to cooperate and exploit opportunities for mutual benefit

- Addressing threats to health, such as emerging infectious diseases
- Learning from each other in areas important to both sides
- Need to address intellectual property rights and compliance



EUROPEAN
COMMISSION

Community Research

Information

- EU research:
<http://europa.eu.int/comm/research>
- Seventh Framework Programme:
http://europa.eu.int/comm/research/future/index_en.cfm
- Information on research programmes and projects:
<http://www.cordis.lu>
- Officer in charge of INCO matters in directorate Health: Indridi.Benediktsson@ec.europa.eu